Compare WYETH LTD with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WYETH LTD vs CADILA HEALTHCARE - Comparison Results

WYETH LTD     Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WYETH LTD CADILA HEALTHCARE WYETH LTD/
CADILA HEALTHCARE
 
P/E (TTM) x 27.7 13.8 200.7% View Chart
P/BV x 5.3 2.3 235.7% View Chart
Dividend Yield % 1.3 1.5 83.8%  

Financials

 WYETH LTD   CADILA HEALTHCARE
EQUITY SHARE DATA
    WYETH LTD
Mar-13
CADILA HEALTHCARE
Mar-19
WYETH LTD/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs1,044432 241.5%   
Low Rs818306 267.0%   
Sales per share (Unadj.) Rs298.6128.6 232.2%  
Earnings per share (Unadj.) Rs57.218.5 308.6%  
Cash flow per share (Unadj.) Rs58.424.4 239.4%  
Dividends per share (Unadj.) Rs17.003.50 485.7%  
Dividend yield (eoy) %1.80.9 192.7%  
Book value per share (Unadj.) Rs249.5101.5 245.9%  
Shares outstanding (eoy) m22.721,023.74 2.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.12.9 108.6%   
Avg P/E ratio x16.319.9 81.7%  
P/CF ratio (eoy) x15.915.1 105.3%  
Price / Book Value ratio x3.73.6 102.5%  
Dividend payout %29.718.9 157.4%   
Avg Mkt Cap Rs m21,157378,170 5.6%   
No. of employees `0000.512.4 4.0%   
Total wages/salary Rs m40021,241 1.9%   
Avg. sales/employee Rs Th13,787.410,585.0 130.3%   
Avg. wages/employee Rs Th813.01,707.8 47.6%   
Avg. net profit/employee Rs Th2,643.31,526.5 173.2%   
INCOME DATA
Net Sales Rs m6,783131,656 5.2%  
Other income Rs m3532,011 17.5%   
Total revenues Rs m7,136133,667 5.3%   
Gross profit Rs m1,61729,731 5.4%  
Depreciation Rs m275,986 0.4%   
Interest Rs m61,935 0.3%   
Profit before tax Rs m1,93823,821 8.1%   
Minority Interest Rs m0469 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-50-   
Tax Rs m6325,303 11.9%   
Profit after tax Rs m1,30118,987 6.8%  
Gross profit margin %23.822.6 105.6%  
Effective tax rate %32.622.3 146.5%   
Net profit margin %19.214.4 132.9%  
BALANCE SHEET DATA
Current assets Rs m6,98484,981 8.2%   
Current liabilities Rs m2,05673,425 2.8%   
Net working cap to sales %72.68.8 827.7%  
Current ratio x3.41.2 293.5%  
Inventory Days Days9975 133.2%  
Debtors Days Days24110 21.9%  
Net fixed assets Rs m244133,493 0.2%   
Share capital Rs m2271,024 22.2%   
"Free" reserves Rs m5,441102,839 5.3%   
Net worth Rs m5,668103,863 5.5%   
Long term debt Rs m2539,497 0.1%   
Total assets Rs m7,901234,831 3.4%  
Interest coverage x353.313.3 2,654.5%   
Debt to equity ratio x00.4 1.2%  
Sales to assets ratio x0.90.6 153.1%   
Return on assets %16.58.9 185.5%  
Return on equity %22.918.3 125.5%  
Return on capital %34.018.3 186.1%  
Exports to sales %0.20-   
Imports to sales %36.30-   
Exports (fob) Rs m15NA-   
Imports (cif) Rs m2,465NA-   
Fx inflow Rs m1548,404 0.0%   
Fx outflow Rs m2,67711,593 23.1%   
Net fx Rs m-2,66236,811 -7.2%   
CASH FLOW
From Operations Rs m92328,823 3.2%  
From Investments Rs m317-57,387 -0.6%  
From Financial Activity Rs m-48118,846 -2.6%  
Net Cashflow Rs m759-7,105 -10.7%  

Share Holding

Indian Promoters % 0.0 74.8 -  
Foreign collaborators % 51.1 0.0 -  
Indian inst/Mut Fund % 11.3 8.3 136.1%  
FIIs % 7.2 5.9 122.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 30.4 11.0 276.4%  
Shareholders   21,978 44,069 49.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WYETH LTD With:   ALKEM LABORATORIES  FRESENIUS KABI ONCO.  FDC LTD.  TORRENT PHARMA  STRIDES PHARMA SCIENCE  

Compare WYETH LTD With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 21 Points Higher; Banking and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest during closing hours today and ended their day marginally higher.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 28.9% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (4QFY19); Net Profit Down 21.0% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 21.0% YoY). Sales on the other hand came in at Rs 37 bn (up 14.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (3QFY19); Net Profit Down 3.7% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 3.7% YoY). Sales on the other hand came in at Rs 36 bn (up 9.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (2QFY19); Net Profit Down 18.6% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, CADILA HEALTHCARE has posted a net profit of Rs 4 bn (down 18.6% YoY). Sales on the other hand came in at Rs 30 bn (down 8.4% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of CADILA HEALTHCARE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

More Views on News

Most Popular

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Ditch the Risky Fixed Deposits for Safer 'Bluechip Deposits'(Profit Hunter)

Oct 30, 2019

Most people think stocks are riskier than fixed deposits and bonds. The last quarter century proves otherwise.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

WYETH LTD SHARE PRICE


Dec 9, 2014 (Close)

TRACK WYETH LTD

  • Track your investment in WYETH LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

WYETH LTD - DIVIS LABORATORIES COMPARISON

COMPARE WYETH LTD WITH

MARKET STATS